Structural insights into SARS‐CoV‐2 main protease conformational plasticity

Abstract

AbstractThe spread of different severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants underscores the need for insights into the structural properties of its structural and non‐structural proteins. The highly conserved homo‐dimeric chymotrypsin‐like protease (3CL MPRO), belonging to the class of cysteine hydrolases, plays an indispensable role in processing viral polyproteins that are involved in viral replication and transcription. Studies have successfully demonstrated the role of MPRO as an attractive drug target for designing antiviral treatments because of its importance in the viral life cycle. Herein, we report the structural dynamics of six experimentally solved structures of MPRO (i.e., 6LU7, 6M03, 6WQF, 6Y2E, 6Y84, and 7BUY including both ligand‐free and ligand‐bound states) at different resolutions. We have employed a structure‐based balanced forcefield, CHARMM36m through state‐of‐the‐art all‐atoms molecular dynamics simulations at µ‐seconds scale at room temperature (303K) and pH 7.0 to explore their structure‐function relationship. The helical domain‐III responsible for dimerization mostly contributes to the altered conformational states and destabilization of MPRO. A keen observation of the high degree of flexibility in the P5 binding pocket adjoining domain II‐III highlights the reason for observation of conformational heterogeneity among the structural ensembles of MPRO. We also observe a differential dynamics of the catalytic pocket residues His41, Cys145, and Asp187, which may lead to catalytic impairment of the monomeric proteases. Among the highly populated conformational states of the six systems, 6LU7 and 7M03 forms the most stable and compact MPRO conformation with intact catalytic site and structural integrity. Altogether, our findings from this extensive study provides a benchmark to identify physiologically relevant structures of such promising drug targets for structure‐based drug design and discovery of potent drug‐like compounds having clinical potential.